Blastocystis subtypes in symptomatic and asymptomatic family members and pets and response to therapy.

Not Applicable

Completed

• Conditions: Irritable bowel like gastrointestinal symptoms in patients positive for Blastocystis carriage in their stool.; Response of symptomatic patients positive for Blastocystis to 14 days of therapy with metronidazole 400 mg three times daily or sulfamethoxazole/trimethoprim 160mg/800mg twice daily.; Specific subtypes of Blastocystis found in symptomatic patients compared to asymptomatic human and animal household members.; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12610001066077
• Lead Sponsor: Dr Rebecca Traub

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-12-03
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Chronic gastrointestinal symptoms

Exclusion Criteria

Other documented cause of gastrointestinal symptoms other than Blastocystis carriage

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Presence or absence of Blastocystis in stool samples before and after antibiotic therapy as assessed by fresh faecal smears, faecal culture and PCR analysis of both faecal specimens and faecal cultures.[Sample time points were baseline (0-2 weeks before therapy), Day 15, 28 and 56.]

Secondary Outcome Measures

Name	Time	Method
To assess how many asymptomatic human and animal household contacts of symptomatic patients were also positive for Blastocystis in their stool and to assess if there was any difference in Blastocystis subtypes between symptomatic and asymptomatic carriers.[Faecal samples were assessed at Day 15 in these groups with fresh faecal smears, faecal cultures and PCR analysis of both faeces and faecal cultures.]